Latest news and press releases about NeoGenomics, Inc. (NEO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
Price
| Price | $19.65 |
| Market Cap | $505M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.66 |
| EV / EBITDA | 58.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -5.03% |
| Return on Assets | -3.84% |
| Gross Margin | 42.92% |
| Operating Margin | -8.63% |
| Net Margin | -6.77% |
Related companies: ACRS · ARCT · HUMA · MDXH · QTRX · SGMT · SMTI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks